Ascendis Pharma (ASND) Update / Briefing June 09, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Ascendis Pharma Coach Trial Interim Top Line Week twenty six Data. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Scott Smith, Executive Vice President and Chief Finan ...

Combination treatment with investigational TransCon CNP and TransCon hGH is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. COACH Trial Interim Topline Week 26 Data June 9, 2025 Cautionary Note on Forward-Looking Statements 2 Combination treatment with investigational TransCon CNP and TransCon hGH is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Executive Summary This present ...

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with ...

– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to placebo – The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition1 COPENHAGEN, ...

COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE & ESE 2025, the joint congress of the European Society for Paediatric ...

Ascendis Pharma (ASND) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Scott Smith - Executive Vice President, Chief Financial OfficerJan Mikkelsen - President and Chief Executive OfficerJay Donovan Wu - EVP & President US MarketTazeen Ahmad - MD - US Equity ResearchGavin Clark-Gartner - Director - Biotechnology Equity ResearchSherrie Glass - Chief Business OfficerAimee Shu - EVP & Chief Medical OfficerJoseph Schwartz - Senior Managing DirectorLi Watsek - DirectorEllie Merle - ED - Biote ...

Ascendis Pharma (ASND) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to Ascendis Pharma First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Fo ...

- Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025 - Conference call today at 4:30 pm ET COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “The strong global launch of ...

Core Viewpoint - Ascendis Pharma A/S will report its first quarter 2025 financial results and provide a business update on May 1, 2025, after U.S. market close, followed by a conference call and live webcast [1] Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on its innovative TransCon technology platform to develop new therapies addressing unmet medical needs [3] - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [3] Event Details - The live webcast for the financial results will be accessible through a provided link, and a replay will be available for 30 days post-event [2]